Johnson & Johnson Stock Valuation: Undervalued or Fairly Priced?
Johnson & Johnson's (JNJ) stock price has surged over the past five years, raising questions about whether its current valuation aligns with the company's cash flows. Using a Discounted Cash Flow (DCF) model, analysts have estimated that JNJ's intrinsic value is above its current share price of $264.74.
The DCF projections assume growing free cash flow over the next decade, with projected annual figures in the $27b to $43b range. This suggests that JNJ's cash flows support its current valuation, but some analysts believe the stock may be undervalued.
Recent clinical results for TECVAYLI plus DARZALEX FASPRO and TREMFYA have improved expectations for future cash generation, which is a positive sign for the company. However, insider share sales are also worth noting, as they may indicate that some executives believe the stock price has reached a plateau.
The DCF model's estimates take into account JNJ's substantial investment in manufacturing, R&D, and technology over the next four years, which is expected to expand capacity for advanced medicines and devices. This investment could drive future growth and justify the current share price.